Insider Buying: Cytosorbents Co. (NASDAQ:CTSO) CFO Buys $19,200.00 in Stock

Cytosorbents Co. (NASDAQ:CTSO) CFO Peter J. Mariani bought 20,000 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $0.96 per share, with a total value of $19,200.00. Following the purchase, the chief financial officer now owns 401,363 shares of the company’s stock, valued at approximately $385,308.48. This represents a 5.24 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Cytosorbents Price Performance

Shares of CTSO opened at $0.86 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents Co. has a 1-year low of $0.70 and a 1-year high of $1.97. The stock has a market cap of $46.92 million, a PE ratio of -2.38 and a beta of 0.57. The firm has a fifty day moving average price of $0.96 and a 200 day moving average price of $1.02.

Institutional Trading of Cytosorbents

Hedge funds and other institutional investors have recently made changes to their positions in the company. Atomi Financial Group Inc. purchased a new position in Cytosorbents during the 3rd quarter worth approximately $51,000. CM Management LLC boosted its holdings in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 25,000 shares during the period. Geode Capital Management LLC grew its position in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC increased its holdings in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on CTSO shares. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. StockNews.com assumed coverage on Cytosorbents in a research note on Thursday, December 12th. They set a “hold” rating for the company.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.